Australian HTA Revamp Aims To Speed Access To New Technologies
Executive Summary
Drug industry group Medicines Australia says that the review of the health technology assessment system must ensure that the real impact and benefits of new products for patients are taken into account in reimbursement decisions. Other areas to be explored include the use of real-world data and managing clinical and economic uncertainty.
You may also be interested in...
Australian Committee Wants HTA Review To Begin Early In 2023
At its next meeting, the Australian committee responsible for reviewing the country's health technology assessment system will discuss feedback from stakeholders, including the pharmaceutical industry, on the draft terms of reference for the review.
Australia To Speed Up Post-Market Reviews Of Reimbursed Drugs
The existing framework for assessing whether medicines should continue to be reimbursed is no longer fit for purpose and requires an overhaul if the ongoing viability of the Pharmaceutical Benefits Scheme is to be ensured, says Australia’s health department.
Australian Industry Signs Deal To Fund Access To Innovative New Drugs
Hot on the heels of Australia’s plan to overhaul the National Medicines Policy comes a new deal with the pharmaceutical industry to make new drugs available as soon as possible after approval and get patients more closely involved in reimbursement processes.